Jiangsu Hengrui Pharmaceuticals (01276): SHR-8925 for Injection Approved to Initiate Clinical Trials

Jiangsu Hengrui Pharmaceuticals (01276) announced that recently, the company's subsidiary Suzhou Suncadia Biopharmaceuticals Co., Ltd. received the Drug Clinical Trial Approval Notice for SHR-8925 for Injection issued and approved by the National Medical Products Administration (hereinafter referred to as the "NMPA"), and will initiate clinical trials in the near future. SHR-8925 for Injection is a therapeutic biologic independently developed by the company that can specifically bind to antigens on the surface of tumor cells and kill tumor cells, and is intended for the treatment of advanced solid tumors. Upon review, no drugs targeting the same target have been approved for marketing domestically or internationally. To date, the cumulative R&D investment in SHR-8925 for Injection and related projects is approximately RMB11.2 million (unaudited).